about
Molecular architecture of the TAP-associated MHC class I peptide-loading complexSevere tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia trachomatisFunctional role of C-terminal sequence elements in the transporter associated with antigen processingBiogenesis of functional antigenic peptide transporter TAP requires assembly of pre-existing TAP1 with newly synthesized TAP2Endoplasmic reticulum export, subcellular distribution, and fibril formation by Pmel17 require an intact N-terminal domain junction.Proprotein convertases process Pmel17 during secretion.A role for UDP-glucose glycoprotein glucosyltransferase in expression and quality control of MHC class I moleculesFunctional significance of tapasin membrane association and disulfide linkage to ERp57 in MHC class I presentationCritical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.Melanosomal formation of PMEL core amyloid is driven by aromatic residues.Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.Hydrophobic Interactions Are Key To Drive the Association of Tapasin with Peptide Transporter Subunit TAP2.Three tapasin docking sites in TAP cooperate to facilitate transporter stabilization and heterodimerization.Post-endoplasmic reticulum rescue of unstable MHC class I requires proprotein convertase PC7.Critical role for the tapasin-docking site of TAP2 in the functional integrity of the MHC class I-peptide-loading complex.Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression.Xenophagic pathways and their bacterial subversion in cellular self-defense - παντα ρει - everything is in flux.Repeat domain-associated O-glycans govern PMEL fibrillar sheet architectureNon-Synonymous variants in premelanosome protein (PMEL) cause ocular pigment dispersion and pigmentary glaucomaCytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen
P50
Q24298182-4EE3D32E-9981-48C4-BE7C-739950BC7986Q24682059-6C177719-0655-4DBD-82E6-5AEF23DB52F8Q28578285-B8B94D6C-6A82-4879-88B2-80B6564A8921Q28583615-81BA4C8B-0F71-4D5A-9C99-9DA71304D600Q33855252-673CA08A-A4BA-4965-98A1-84270F54105BQ34685446-0A82FAE4-7834-4B08-B5C2-5DBF18EFB783Q34720949-D8252712-41AA-4B07-A0DB-7A94C1838C8CQ36452717-6B985FD1-8406-4DF9-B2DA-1547F43731CBQ36717393-01E0A2D3-ED07-4501-9AA7-D3B48A32B77EQ37685780-7B9CE052-D9C6-443F-8CB6-1E9000E52A34Q37969745-E8F6F2A9-D15D-4626-AFD5-72E6D0E711BDQ38823378-EC1D5FED-3684-4DA1-A65B-C93F5CCF95FEQ39026675-B1746646-48C2-4E88-8613-13573049CABDQ39738040-F60E9827-83D1-4056-A206-060D24506594Q40364703-58220F27-B1E1-4CFD-807D-C046F1FF47CAQ42030463-B3774798-13BE-427D-A724-A015C6A9D8B5Q47184184-E9DE223D-DE5D-42CB-8E4A-3C931F907609Q64115757-33C24542-A87F-4844-9CC8-0C917664958CQ90610396-1A22A9BC-30D0-4680-B54F-63BC4B361314Q91088038-8315C315-B1F0-4E62-AD95-CF4CD5ABB23D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ralf Max Leonhardt
@ast
Ralf Max Leonhardt
@en
Ralf Max Leonhardt
@es
Ralf Max Leonhardt
@nl
Ralf Max Leonhardt
@sl
type
label
Ralf Max Leonhardt
@ast
Ralf Max Leonhardt
@en
Ralf Max Leonhardt
@es
Ralf Max Leonhardt
@nl
Ralf Max Leonhardt
@sl
prefLabel
Ralf Max Leonhardt
@ast
Ralf Max Leonhardt
@en
Ralf Max Leonhardt
@es
Ralf Max Leonhardt
@nl
Ralf Max Leonhardt
@sl
P106
P21
P31
P496
0000-0001-6673-8217